News Sentiment

APS sentiment intelligence

Aptose Biosciences Inc. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 50 Balanced news tone 7 relevant articles
Exchange TOR Canada
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 2.20 Week of 19 Jun 2026
Weighted tone 50/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 7

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.5% over one week, -7.6% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Aptose reports 86% response rate in AML triplet therapy trial By Investing.com

Market Reaction

Balanced read

47/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 0.5% Price digesting
Trend fit Trend inactive -7.6% over four weeks
Fair value -2.4% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 0
Neutral 7
Negative 0

Relevance

Why the article matched

Direct first
Direct company coverage 7
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
GlobeNewswire 4
MarketBeat 2
Investing.com Canada 1

Event Lens

What the news is about

Classified themes
Market update 5
Earnings 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-7 of 7